With a growing attention focused on vascular calcification, evolving evidence suggests that it is one of the major causes of CVD in patients with CKD.

While research is focused on the pathophysiology and clinical impact of vascular calcification as an important aspect of CKD-MBD, less attention has been given to cardiac valve calcification in patients with CKD.

However, it has been reported to be associated with a higher risk of CVD and death in patients with CKD.

Cardiac valve calcification has high incidence in patients with CKD.

Low Vitamin D levels are linked with vascular calcification in CKD.

Study revealed serum 1, 25 (OH)₂D level may be a potential biomarker of AVC and MVC in these patients.

Future studies are needed to delineate the role of Vitamin D in the pathogenesis of cardiac valve calcification in CKD.

Future studies will also determine whether Vitamin D therapy can prevent the progression of cardiac valve calcification in patients with CKD.

Reference: Kim IY, Ye BM, Kim MJ, et al. 1, 25-dihydroxyvitamin D deficiency is independently associated with cardiac valve calcification in patients with chronic kidney disease. Scientific Reports. 2022; Article number 915. DOI: 0.1038/s41598-022-04981-x